Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Cohen

Pain Medicine Dallas, TX Medical Doctor

NPI 1962516112 CMS profile 88537

4004 Worth St, Suite 300, Dallas, TX 75246

Open in the dashboard

General payments

$5,534

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Cohen of Dallas, TX is reported in the CMS Open Payments database as having received $5,534 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $644 34
2024 General $375 22
2023 General $722 27
2022 General $766 35
2021 General $859 43
2020 General $477 24
2019 General $1,690 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Cohen
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Howard Cohen were reported at $644. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Howard Cohen Pain Medicine median Middle half National median
2019 $1,690 $298 $103–$1,153 $163
2020 $477 $188 $57–$916 $114
2021 $859 $365 $109–$1,150 $132
2022 $766 $498 $104–$1,575 $149
2023 $722 $334 $108–$1,267 $160
2024 $375 $544 $144–$1,302 $164
2025 $644 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,178 60 payments
  2. Amgen Inc. $504 18 payments
  3. Teva Pharmaceuticals USA, Inc. $484 28 payments
  4. Allergan Inc. $436 16 payments
  5. Otsuka America Pharmaceutical, Inc. $298 18 payments
  6. Avanir Pharmaceuticals, Inc. $285 11 payments
  7. ITI, Inc. $230 6 payments
  8. Collegium Pharmaceutical, Inc. $225 13 payments
  9. Lilly USA, LLC $194 11 payments
  10. Medtronic, Inc. $169 1 payment
  11. Other $1,531 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,534 266 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $595 24 payments
  2. QULIPTA $472 22 payments
  3. UBRELVY Neuroscience $390 14 payments
  4. VRAYLAR Neuroscience $384 24 payments
  5. VRAYLAR Neuroscience $376 17 payments
  6. NUEDEXTA $285 11 payments
  7. REXULTI $284 17 payments
  8. AJOVY $213 9 payments
  9. EMGALITY $194 11 payments
  10. UBRELVY Neuroscience $187 6 payments
  11. Other $2,562 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

177

Median for Neuropsychiatry: 88

Drug cost

$2,553

Median for Neuropsychiatry: $2,689

Branded share of claims

36.7%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 33 $1,195
Gabapentin Generic 33 $445
Ondansetron Odt Ondansetron Brand 18 $208
Tizanidine Hcl Generic 16 $206
Venlafaxine Hcl Er Venlafaxine Hcl Brand 14 $150
Quetiapine Fumarate Generic 13 $118
Lithium Carbonate Generic 11 $93
Escitalopram Oxalate Generic 28 $92
Celecoxib Generic 11 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $174
$174 — —
QULIPTA
  • AbbVie, Inc. $66
$66 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $39
$39 — —
NURTEC ODT
  • PFIZER INC. $37
$37 — —
UBRELVY
  • AbbVie, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record